Verified Document

Medical Devices: FDA Should Take Steps To Research Paper

Medical devices: FDA should take steps to ensure that high -Risk device types are approved through the most stringent premarket review process. Medical Device Reporting (MDR)

Medical Device Reporting (MDR) is the name of the Act that allocates control to the Food and Drug Administration to monitor results of medical devices in order to make sure that no adverse effects results to society. The FDA receives information on this account from all manufacturers, users, and importers of medical devices who, if they experience a problem, are obligated to report this problem to the FDA so that these problems can be treated directly. User Facilities (e.g., hospitals, nursing homes), moreover, are required to report these problems to both the FDA and the manufacturer. Even if the user facility only suspects a serious result to have occurred because of the device but is not certain, nonetheless, the suspicions should still be reported to both FDA and manufacturer. If the medical device manufacturer is unknown, the serious injury is reported by the facility to the FDA.

The FDA urges that:

If you are a consumer or health professional you should use the MEDWATCH program for reporting significant adverse...

A 1986 General Accounting Office (GAO) study showed that less than one percent of device problems occurring in hospitals were being reported to FDA, and that the more serious the problem with a device, the less likely it was to be reported. In 1989, a GAO follow-up study showed that serious lapses of reporting to FDA still existed. Incidents that involved device-related deaths, serious injuries, and certain malfunctions were still being seriously under-reported.
The Safe Medical Devices Act of 1990 (SMDA) obligated device user facilities to report device-related deaths to the FDA and to the manufacturer. On November 28, 1991, SMDA also required that device user facilities submit to FDA, every six months, a summary of all reports submitted during that time period. This Amendment became law on June 16, 1992,…

Sources used in this document:
Source

Medical Device Reporting - General Information www.rcb.ca.gov/forms_pubs/attach6.pdf

FDA - Medical Device Reporting (MDR) http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm
Cite this Document:
Copy Bibliography Citation

Related Documents

FDA Classification the FDA Is
Words: 577 Length: 2 Document Type: Term Paper

Given that there is no expectation of substantial equivalence, the following process will need to be undertaken. The 510(K) that needs to be submitted is the Traditional. A Special is for modifications to products that already have 510(k) approval, so that does not apply in this case. An Abbreviated 510(K) applies when a product is approved for this process by the FDA. There is little explanation on the FDA website

Nanotechnology Medical
Words: 922 Length: 3 Document Type: Essay

Health Care Bill The purpose of this work is to outline the legislative process and propose valuable new legislation. There are several learners objectives. The first is to understand the legislative process. The second is to be able to understand and identify gaps in the present regulatory environment. The third is to be able to gain an understanding of the wording of health care laws. There is a wide range of health

Translating Biomedical Innovation Mental Health and Well-Being
Words: 4501 Length: 14 Document Type: Term Paper

Translating Biomedical Innovation / Mental Health and well being Managing Ideas: Commercialization Strategies for Biotechnology This article by Joshua and Scott Focuses on the commercialization aspect of biotechnology and stresses how important it is for innovators in the new and fast developing field of biotechnology to effectively forge collaboration with existing pharmaceutical market leaders in order to successfully create a new and strong value proposition for the healthcare sector. Biotech firms have

Biotechnology Business Focused on Charles
Words: 5076 Length: 20 Document Type: Term Paper

PK = Deltagen Inc. PRXL = Parexel International Corp. Pvt1 = Quintiles Transnational Corp. (privately held) Industry = Biotechnology As of 2005 Source: Yahoo! Finance, April 29, 2007. Figure 1. Financial Performance: Charles River Laboratories vs. Deltagen Inc. And Parexel International Corp. - January 2002 to date. Source: Yahoo! Finance, April 29, 2007. Operating income for 2006 was reported by the company to be $188.2 million compared to $184.7 million for 2005 and its operating margin for 2006

Health Information Systems
Words: 359 Length: 1 Document Type: Term Paper

PDI's financial condition. Review relevant financial information. Like most companies providing solutions to the biopharma industry, PDI has felt some of the negative effects of what is happening throughout the industry. [PDI's Finances] PDI is a commercialization partner providing solutions to the biopharma and medical devices and diagnostics industries. The industry is very volatile right now and the need for contract sales has been diminished. This was a large portion of PDI's business.

New Technology the Best Cure
Words: 13809 Length: 50 Document Type: Term Paper

Taken in isolation, some of the new, minimally-invasive procedures are less expensive by far, when analyzed on a procedure-by-procedure basis, than previous significant surgical interventions, as demonstrated below: Procedure Cost Estimated duration of 'cure' CABG 5-7 years PCI (percutaneous coronary intervention 3-5 years Based on the above analysis, it would appear to be clear that a PCI is more cost-effective than CABG procedures. This may not be true when all costs are considered, however. The logic of

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now